Evinova, an AstraZeneca‑launched AI‑native clinical development unit, signed deals with Astellas, Bristol Myers Squibb and parent AstraZeneca to deploy its AI platform for study design optimization and document management. Under the agreements, partners will share operational trial data in exchange for access to benchmarks and AI‑driven recommendations intended to accelerate trial timelines. Evinova said the collaborations reflect demand for an AI‑native platform that standardizes operational best practices across sponsors and CROs. The company will use aggregated operational datasets to generate recommendations aimed at reducing trial duration and administrative burden. Industry participants said the deals mark a shift from pilots to enterprise‑scale AI deployments in clinical operations, with data‑sharing partnerships emerging as the commercial model to monetize operational algorithms while preserving sponsor control over clinical assets.